X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Acquired by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc lifted its stake in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 4.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,546,458 shares of the company’s stock after purchasing an additional 111,032 shares during the quarter. Ensign Peak Advisors Inc’s holdings in X4 Pharmaceuticals were worth $1,477,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of XFOR. Bain Capital Life Sciences Investors LLC raised its position in X4 Pharmaceuticals by 6.0% during the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 16,915,784 shares of the company’s stock worth $14,184,000 after buying an additional 955,196 shares during the last quarter. Kingdon Capital Management L.L.C. raised its holdings in X4 Pharmaceuticals by 76.0% during the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,473,683 shares of the company’s stock worth $2,913,000 after purchasing an additional 1,500,000 shares in the last quarter. Bank of New York Mellon Corp lifted its position in X4 Pharmaceuticals by 39.7% in the second quarter. Bank of New York Mellon Corp now owns 469,372 shares of the company’s stock valued at $272,000 after purchasing an additional 133,398 shares during the period. XTX Topco Ltd purchased a new stake in X4 Pharmaceuticals in the 2nd quarter valued at approximately $65,000. Finally, Rhumbline Advisers increased its position in X4 Pharmaceuticals by 14.6% during the 2nd quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock worth $109,000 after purchasing an additional 23,831 shares during the period. 72.03% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of X4 Pharmaceuticals in a report on Friday, June 28th.

X4 Pharmaceuticals Stock Performance

NASDAQ:XFOR opened at $0.66 on Friday. The firm’s fifty day simple moving average is $0.71 and its 200-day simple moving average is $0.92. The company has a quick ratio of 6.04, a current ratio of 6.07 and a debt-to-equity ratio of 0.79. The stock has a market cap of $110.00 million, a PE ratio of -0.94 and a beta of 0.36. X4 Pharmaceuticals, Inc. has a fifty-two week low of $0.53 and a fifty-two week high of $1.60.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its earnings results on Thursday, August 8th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.03). The business had revenue of $0.56 million for the quarter, compared to the consensus estimate of $52.98 million. During the same quarter in the prior year, the firm earned ($0.33) EPS. Analysts expect that X4 Pharmaceuticals, Inc. will post -0.65 earnings per share for the current fiscal year.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.